Stay updated on Subcutaneous Daratumumab with Bispecific Antibodies Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Daratumumab with Bispecific Antibodies Clinical Trial page.

Latest updates to the Subcutaneous Daratumumab with Bispecific Antibodies Clinical Trial page
- Check5 days agoChange DetectedAdded Related Topics: Multiple Myeloma and MedlinePlus Genetics, and added the TRIMM-2 Blood 2025 publication reference; removed the earlier Blood 2025 online-ahead-of-print reference.SummaryDifference0.2%

- Check12 days agoChange DetectedNew locations are listed for the study, including California, New York, North Carolina, Pennsylvania, Tennessee, Wisconsin, and also Alberta and Ontario in Canada. Locations headings for individual states/provinces were removed in favor of a consolidated Locations section, and the page revision version updated to v3.3.3.SummaryDifference0.8%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page shows updates to the study record dates and related metadata (e.g., Last Update Posted 2025-12-05). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check33 days agoChange DetectedThe page no longer lists 'Multiple myeloma' and its related topics (MedlinePlus Genetics). This reduces disease context for the study.SummaryDifference0.1%

- Check41 days agoChange DetectedPublications section description updated to indicate PubMed auto-fills publications and that listed articles may not be about the study; revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check48 days agoChange DetectedAdministrative updates include adding the Last Update Posted (Estimated) timestamp and MedlinePlus Genetics related topics, and removing a funding-lapse notice; these changes do not modify the study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

Stay in the know with updates to Subcutaneous Daratumumab with Bispecific Antibodies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Daratumumab with Bispecific Antibodies Clinical Trial page.